|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
EGCG as an anti-SARS-CoV-2 agent: Preventive versus therapeutic potential against original and mutant virusстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 27 октября 2021 г.
- Авторы: Tsvetkov Vladimir, Varizhuk Anna, Kozlovskaya Liubov, Shtro Anna, Lebedeva Olga, Komissarov Andrey, Vedekhina Tatjana, Manuvera Valentin, Zubkova Olga, Eremeev Artem, Shustova Elena, Pozmogova Galina, Lioznov Dmitry, Ishmukhametov Aydar, Lazarev Vassili, Lagarkova Maria
- Журнал: Biochimie
- Том: 191
- Год издания: 2021
- Издательство: Elsevier BV
- Местоположение издательства: Netherlands
- Первая страница: 27
- Последняя страница: 32
- DOI: 10.1016/j.biochi.2021.08.003
- Аннотация: In the search for anti-SARS-CoV-2 drugs, much attention is given to safe and widely available native compounds. The green tea component epigallocatechin 3 gallate (EGCG) is particularly promising because it reportedly inhibits viral replication and viral entry in vitro. However, conclusive evidence for its predominant activity is needed. We tested EGCG effects on the native virus isolated from COVID-19 patients in two independent series of experiments using VERO cells and two different treatment schemes in each series. The results confirmed modest cytotoxicity of EGCG and its substantial antiviral activity. The preincubation scheme aimed at infection prevention has proven particularly beneficial. We complemented that finding with a detailed investigation of EGCG interactions with viral S-protein subunits, including S2, RBD, and the RBD mutant harboring the N501Y mutation. Molecular modeling experiments revealed N501Y-specific stacking interactions in the RBD-ACE2 complex and provided insight into EGCG interference with the complex formation. Together, these findings provide a molecular basis for the observed EGCG effects and reinforce its prospects in COVID-19 prevention therapy.
- Добавил в систему: Tsvetkov Vladimir Borisovich